Want to see IN:LASA full AI Analyst Report?
LASA Stock Chart & Stats
₹6.82
-₹0.12(-1.73%)
At close: 4:00 PM EDT
₹6.82
-₹0.12(-1.73%)
Day’s Range― - ―
52-Week Range₹5.65 - ₹14.14
Previous CloseN/A
Volume22.89K
Average Volume (3M)39.13K
Market Cap
₹348.20M
Enterprise Value₹471.28M
Total Cash (Recent Filing)₹6.97M
Total Debt (Recent Filing)₹97.47M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.31
Shares Outstanding50,101,240
10 Day Avg. Volume9,122
30 Day Avg. Volume39,131
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)1.13
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageSustained low debt-to-equity (~0.20) provides durable financial flexibility: it reduces bankruptcy risk, limits interest burden, and gives management runway to restructure operations or fund working capital. Over 2–6 months this supports survival while operational fixes are implemented.
B2B API Manufacturing Business ModelA B2B API supplier model targets formulators and finished-dose manufacturers, creating recurring demand, larger purchase contracts, and higher switching costs than retail channels. Structural demand across therapeutic categories supports baseline revenue potential if production and compliance are maintained.
Past Operating Cash GenerationHistorical episodes of positive operating cash flow (FY2024, strong in FY2021) indicate the business can generate cash when utilization and pricing align. This suggests turnaround is feasible through cost control, plant utilization improvement, or customer recovery, supporting medium-term recovery plans.
Bears Say
Sharp Revenue DeclineA ~74% revenue collapse signals loss of volume, customers, or product demand and destroys scale economies. Reduced topline undermines margin recovery, limits ability to cover fixed costs, and makes restoring profitability a multi-quarter structural challenge rather than a short-term blip.
Deeply Negative MarginsNegative gross and net margins show core operations are unprofitable, not just a financing issue. This erodes equity, prevents reinvestment, and requires substantive changes—product mix, pricing, cost structure, or asset disposals—to reach sustainable profitability over the coming months.
Inconsistent And Negative Cash GenerationRecurring negative operating cash flow and pressured free cash flow reduce internal funding capacity, increasing reliance on external financing or equity. That constrains investment in compliance, capacity, or sales efforts and raises solvency risk if losses persist beyond a few quarters.
Lasa Supergenerics Ltd. News
LASA FAQ
What was Lasa Supergenerics Ltd.’s price range in the past 12 months?
Lasa Supergenerics Ltd. lowest stock price was ₹5.65 and its highest was ₹14.14 in the past 12 months.
What is Lasa Supergenerics Ltd.’s market cap?
Lasa Supergenerics Ltd.’s market cap is ₹348.20M.
When is Lasa Supergenerics Ltd.’s upcoming earnings report date?
Lasa Supergenerics Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 16 days.
How were Lasa Supergenerics Ltd.’s earnings last quarter?
Lasa Supergenerics Ltd. released its earnings results on May 29, 2026. The company reported -₹0.83 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.83.
Is Lasa Supergenerics Ltd. overvalued?
According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued.
Does Lasa Supergenerics Ltd. pay dividends?
Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Lasa Supergenerics Ltd. dividends here
What is Lasa Supergenerics Ltd.’s EPS estimate?
Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lasa Supergenerics Ltd. have?
Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.
What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?
Lasa Supergenerics Ltd. reported an EPS of -₹0.83 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.217%.
Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?
Currently, no hedge funds are holding shares in IN:LASA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lasa Supergenerics Ltd.
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.
Technical Analysis
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―